

## Special Issue

# Vaccine, Preventive Strategies and Antiviral Responses to Zoonotic Viruses

### Message from the Guest Editors

We are now facing a world increasingly affected by viral zoonoses entering the human society. Vaccines remain the top priority for preventing infectious diseases, yet many viral zoonotic pathogens, especially emerging ones, lack licensed vaccines. This Special Issue aims to publish recent progress on vaccine development and efficacy evaluation, immune responses and immunologic mechanisms, as well as development of animal models against various zoonotic viral pathogens. Those include numerous viral pathogens that are characterized by different taxonomic categories, including Alphavirus, Arenavirus, Bunyavirus, Coronavirus, Flavivirus, Filovirus, Orthopoxvirus, Orthomyxovirus, Paramyxovirus, Rhabdovirus, etc. For this Special Issue, research areas may include (but are not limited to) the following areas:

- Animal models for viral zoonoses;
- Vaccine development and efficacy evaluation for viral zoonoses;
- Immune responses to vaccines and the underlying immunologic mechanisms;
- Adjuvants and immunomodulators for vaccines;
- Next-generation vaccine technology;
- Clinical trials of vaccines;
- Epidemiology and significance of viral mutation for vaccine efficacy.

---

### Guest Editors

Dr. Wei Ye

Dr. Shu Shen

Prof. Dr. Chen Peng

Dr. Ben Hu

---

### Deadline for manuscript submissions

31 May 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/211387](https://mdpi.com/si/211387)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).